Drug Metabolism and Disposition Fast Forward
First published on June 28, 2007; DOI: 10.1124/dmd.107.015743
0090-9556/07/3510-1733-1736$20.00
DMD 35:1733-1736, 2007
Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes
H. F. Perrett,
Z. E. Barter,
B. C. Jones,
H. Yamazaki,
G. T. Tucker, and
A. Rostami-Hodjegan
Academic Unit of Clinical Pharmacology, University of Sheffield, Royal Hallamshire Hospital, Sheffield, United Kingdom (H.F.P., Z.E.B., G.T.T., A.R.-H.); Simcyp Ltd., Sheffield, United Kingdom (Z.E.B., G.T.T., A.R.-H.); Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (B.C.J.); and Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo, Japan (H.Y.)
(Received March 9, 2007;
Accepted June 25, 2007)
 |
Abstract
|
|---|
An analysis of reported hepatic abundances of CYP3A4 and 3A5 indicated that values determined by immunoquantification using commercially available, unpurified recombinant enzymes as standards are significantly lower than those determined using purified enzymes or human liver microsomes characterized with lysosomal peptides (CYP3A4: mean 45 versus 121 pmol/mg protein, p < 0.01; CYP3A5: mean 28 versus 83 pmol/mg protein, p < 0.05). When immunoquantifying cytochromes P450 (P450s), it is assumed that the holoprotein (holo)/apoprotein ratio is the same in the samples and the standard. Estimates of holo/apoprotein ratios from data reported for a range of P450s purified from human liver and non-commercial recombinant systems indicated less than complete and variable heme coupling dependent on enzyme and system.
The absolute abundances of cytochrome P450 (P450) enzymes in human liver, expressed as amount of enzyme per milligram of microsomal protein, are required for scaling of in vitro data on drug metabolism by recombinant human P450 systems (rhP450) to in vivo hepatic clearance (Barter et al., 2007
). The use of intersystem extrapolation factors (Proctor et al., 2004) allows the differences in intrinsic activity (per unit P450) between rhP450 and human liver enzymes to be accounted for. The corrected rhP450 in vitro data must then be combined with the abundance of the appropriate P450 enzyme in human liver as part of the scaling process. If such abundances are established for large numbers of individual human livers, it is possible to combine this information with activity per unit enzyme obtained with rhP450 systems to predict the distribution of drug clearance across populations, without the need to assess enzyme activity directly in large numbers of liver samples (Rostami-Hodjegan and Tucker, 2007). The accuracy of such in vitro-in vivo predictions will clearly depend on the fidelity of estimates of individual P450 abundances in human liver. The latter are usually determined by immunoblotting (Laemmli, 1970) or enzyme-linked immunosorbant assay. More recently, mass spectrometric methods have also been proposed for P450 quantification in human samples (Lane et al., 2004; Alterman, 2005; Jenkins et al., 2006). However, all of these methods measure apoprotein, which comprises active protein in which heme is incorporated (holoprotein), and that in which it is not. By contrast, only holoprotein is measured by carbon monoxide (Omura and Sato, 1964) or dithionite difference spectroscopy (Matsubara et al., 1976). A variety of protein standards have been used to immunoquantify P450s in human liver microsomes, ranging from enzyme purified to electrophoretic homogeneity from either liver microsomes or rhP450s (Guengerich and Turvy, 1991; Shimada et al., 1994), human liver microsomal standard (HLMSTD) (Westlind Johnsson et al., 2003) characterized using lysozyme-peptide conjugates (Edwards et al., 1998), to (more recently) commercially available (unpurified) rhP450 systems (King et al., 2003; Galetin et al., 2004; Wang et al., 2005). An assumption in using any of these standards is that the holoprotein/apoprotein ratio is the same in the samples and the standard. To our knowledge the implications of this assumption have never been assessed.
The aims of this study were 2-fold: first, to carry out a meta-analysis of CYP3A4 and 3A5 abundance values determined using different calibration standards, and second, to assess holoprotein/apoprotein ratios from studies reporting the purification of P450s from human liver and recombinant systems.
|
Materials and Methods
|
|---|
Abundances of CYP3A4 and CYP3A5 in Human Liver. Values of human hepatic CYP3A4 and CYP3A5 abundance were collated from two electronic databases, MEDLINE (http://www.nlm.nih.gov/databases/databases_medline.html) and Web of Knowledge (http://wok.mimas.ac.uk/), and personal files of the authors (1990-2006) containing references from "Current Contents" and "Reference Updates". The authors of the original articles were contacted directly when further information was required. Only data from adult Caucasians (>16 years) were included, and sources were verified to exclude duplication of individual data in the analysis. Geometric mean values of abundance were used to represent central tendency since the frequency distributions of the data were not normal (Kolmogorov-Smirnov test; SPSS v12, SPSS Inc., Chicago, IL). Overall weighted mean (W
) values of CYP3A4 and CYP3A5 abundance were calculated using eq. 1:
 | (1) |
where there are J sources of data, n samples in each source, and 
is the mean value from each data source. The weighted geometric mean values (Wgeo) were calculated using eq. 2:
 | (2) |
where CV is the coefficient of variation (%).
Heterogeneity in the data was assessed from the homogeneity number (HMG), calculated using eqs. 3 to 5:
 | (3) |
 | (4) |
 | (5) |
where wj is the weight of each study based on the variance of the data and VW is the variance of the weighted mean of all observations (1-J).
The significance of differences between CYP3A4 and CYP3A5 abundance values determined from studies using rhP450 standards and those using HLMSTD or purified enzyme were assessed by Student's t test (Data Analysis Toolpack, Microsoft Office Excel 2003; Microsoft, Redmond, WA).
Determination of Holoprotein/Apoprotein Ratios of Purified P450s. The MEDLINE database was searched for reports of P450 enzyme purification from both human liver microsomes and recombinant expression systems. The molecular mass (kDa) of each P450 (CYP1A2, 58.3; 2A6, 56.5; 2B6, 56.3; 2C8, 55.8; 2C9, 55.6; 2C19, 56.0; 2D6, 55.8; 2E1, 56.9; 3A4, 57.3; 3A5, 57.1) was used to calculate the expected specific enzyme content, assuming 100% holoprotein. The actual percentage holoprotein content of each preparation was calculated using eq. 6 by comparing the measured value of the specific P450 content per milligram of total protein determined by spectroscopy with the expected value
 | (6) |
Deviation of holoprotein protein contents from 100% were assessed for each P450 using the z-test. Differences in holoprotein content between P450s were assessed by one-way analysis of variance followed by Tukey's b post hoc test.
|
Results
|
|---|
The analysis of CYP3A4 abundance values was based on 384 livers from 13 separate studies (Table 1). The overall weighted geometric mean value was 82 pmol/mg microsomal protein, and there was a 10-fold difference between mean estimates from different studies. The homogeneity test gave an HMG of 37 (p < 0.001), indicating that the reported average values of abundance in these studies did not conform to a unimodal distribution. Accordingly, the mean value of CYP3A4 abundance determined from studies using rhP450 systems as the calibration standard was significantly lower (p < 0.01) than the mean value from studies using characterized human liver microsomes or purified enzyme (45 versus 121 pmol/mg microsomal protein). In all of the studies included in the meta-analysis, rhP450 enzymes were obtained from commercial sources.
The analysis of CYP3A5 abundance values was based on 45 livers from seven separate studies (Table 2). The overall weighted geometric mean value was 55 pmol/mg microsomal protein, and there was an 8-fold difference between mean estimates from different studies. An HMG value of 53 indicated significant (p < 0.001) heterogeneity in the results of the different studies. Accordingly, the mean value of CYP3A5 abundance determined from studies using rhP450 systems as the calibration standard was significantly lower (p < 0.05) than the mean value from studies using characterized human liver microsomes or purified enzyme (28 versus 83 pmol/mg microsomal protein).
The percentage contributions of holoprotein to total P450 protein purified from human liver were found to be significantly less than 100% (p < 0.01 for CYP2C19 and p < 0.001 for CYP2C8, 2C9, 2D6, and 3A4) and the mean holoprotein/apoprotein ratio for CYP2D6 preparations was significantly (p < 0.05) less than that of the other P450 preparations (Fig. 1A). There were also indications of intersubject differences in holoprotein proportion, as exemplified by the analysis of data for CYP3A4 in preparations from three different livers purified in the same laboratory (Fig. 1B). The percentage contributions of holoprotein to total P450 protein purified from rhP450 systems are shown in Fig. 2. Unlike the rhP450 preparations used in the meta-analysis of CYP3A4 and CYP3A5 abundance, rhP450s used to obtain purified enzyme were from noncommercial sources.
View larger version (17K):
[in this window]
[in a new window]
|
FIG. 1. A, mean percentage contribution of P450 enzyme holoprotein to total P450 protein in preparations purified from human liver tissue. Standard deviations are shown by error bars where the number of livers was sufficient for calculation. B, interindividual variability in percentage contribution of holoprotein to total CYP3A4 protein purified from three individual livers (from Guengerich et al., 1986). (References to the data for each of the P450s in A are 1A2: Distlerath et al. 1985; 2A6: Yun et al., 1991; 2C8: Wang et al., 1980; Wrighton et al., 1987b; Lasker et al., 1998; 2C9: Shimada et al., 1986; Kawano et al., 1987; Lasker et al., 1987, 1998; Komori et al., 1988; Sandhu et al., 1993; 2C19: Lasker et al., 1987, 1998; 2D6: Gut et al., 1984, 1986; Dislerath et al., 1985; 2E1: Lasker et al., 1987; Wrighton et al., 1987a; 3A4: Wang et al., 1983; Watkins et al., 1985; Guengerich et al., 1986; Kawano et al., 1987; Komori et al., 1988; Lin et al., 2002.)
|
|
View larger version (34K):
[in this window]
[in a new window]
|
FIG. 2. Percentage holoprotein contribution in preparations purified from recombinant P450 expression systems. For comparison, the dotted lines indicate the mean percentage holoprotein contribution observed for each P450 enzyme when purified from human liver tissue.
|
|
|
Discussion
|
|---|
The study of CYP3A4 and CYP3A5 abundances in human liver indicated that the use of different protein standards may result in different values, with commercial rhP450 standards providing generally lower estimates than characterized human liver microsomes and purified enzyme preparations (Tables 1 and 2). A possible explanation for the latter observation is that different standards have different holoprotein/apoprotein ratios. Thus, if the standard contains a lower proportion of holoprotein than that in the samples, the same immunoblot signal will indicate a lower amount of active enzyme, resulting in an underprediction of active P450 abundance in the samples.
Estimates of the holoprotein/apoprotein ratios of purified P450s from human liver indicate incomplete heme coupling, and differences in this respect between specific P450s and possibly between individual livers (Fig. 1). Although incomplete protein purification may explain the findings, it is unlikely that contamination would be more than 10% since loading of 5 µg of protein on a gel is usually sufficient to detect bands from other proteins running separately from the "pure" enzyme. Thus, incomplete purification cannot account for the greater than 10% differences in holoprotein/apoprotein ratios observed in many cases. If incomplete purification can be discounted, the observations are either due to incomplete heme incorporation in vivo or experimental artifact (uncoupling of the heme from P450 protein during the purification process), or both. The latter assumes that the uncoupling happens to different extents in different purified systems. In any event, the findings have important implications for the immunoquantification of P450 abundances in human liver samples if there is a mismatch of the holoprotein/apoprotein ratio in standards and samples. Depending on the standard used, there could be either under- or overprediction of P450 abundance.
The estimated holoprotein contents of purified rhP450s also suggest incomplete heme coupling. The majority of purified rhP450 preparations have a holoprotein/apoprotein ratio similar to that seen in the human liver preparations, suggesting that these would be suitable to use as standards for immunoquantification (Fig. 2). However, the CYP2D6 preparations had higher holoprotein contents than that seen in the human liver preparations. Therefore, if these were used as a standard, a significant overprediction in CYP2D6 abundance would result. It should be noted that these rhP450 standards have not been produced for commercial use. The low estimations of P450 abundance indicated in Tables 1 and 2 suggest that commercially available recombinantly expressed P450 systems would have a lower holoprotein content than those shown in Fig. 2.
The observation that estimates of CYP3A abundances are lower when using commercially available rhP450 systems as standards relative to human liver standards could reflect a lower holoprotein/apoprotein ratio in these systems. To establish whether this is the case, it would be necessary to show that the commercial rhP450 systems give a greater immunoblot signal for the same level of spectrally determined holoprotein compared with purified liver enzyme. Preliminary studies have suggested that this is the case for CYP3A4 and CYP3A5 rhP450 systems (Wilson et al., 2005; Perrett et al., 2006). This work is ongoing, and we hope that the outcome will enable determination of appropriate correction factors to apply when measuring enzyme abundance with rhP450 systems. The utility of such factors would also depend on the extent of variability in the holoprotein/apoprotein ratio between individual liver samples. It is possible that the ratio of holoprotein to apoprotein might also be affected by genotype since single residue changes can markedly affect protein stability.
|
Acknowledgments
|
|---|
We thank Dr. K. Rowland Yeo for assistance with the meta-analysis of P450 abundances.
|
Footnotes
|
|---|
H.F.P. and Z.E.B. were supported by Simcyp Ltd., Sheffield, UK, and EU Framework 6 (BIOSIM).
doi:10.1124/dmd.107.015743.
ABBREVIATIONS: P450, cytochrome P450; rhP450, recombinant human cytochrome P450; HLMSTD, human liver microsomal standard; W, weighted mean; HMG, homogeneity number; VW, variance of the weighted mean.
Address correspondence to: Dr. Zoe Barter, Floor M, The Royal Hallamshire Hospital, Sheffield S10 2JF, U.K. E-mail: z.barter{at}sheffield.ac.uk
|
References
|
|---|
Alterman MA, Kornilayev B, Duzhak T, and Yakovlev D (2005) Quantitative analysis of cytochrome P450 isozymes by means of unique isozyme-specific tryptic peptides: a proteomic approach. Drug Metab Dispos 33: 1399-1407.[Abstract/Free Full Text]
Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen O, et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8: 33-45.[CrossRef][Medline]
Chen W, Peter RM, McArdle S, Thummel KE, Sigle RO, and Nelson SD (1996) Baculovirus expression and purification of human and rat cytochrome P450 2E1. Arch Biochem Biophys 335: 123-130.[CrossRef][Medline]
Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, and Guengerich FP (1985) Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260: 9057-9067.[Abstract/Free Full Text]
Edwards RJ, Adams DA, Watts PS, Davies DS, and Boobis AR (1998) Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 56: 377-387.[CrossRef][Medline]
Galetin A, Brown C, Hallifax D, Ito K, and Houston JB (2004) Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metab Dispos 32: 1411-1420.[Abstract/Free Full Text]
Gillam EM, Baba T, Kim BR, Ohmori S, and Guengerich FP (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys 305: 123-131.[CrossRef][Medline]
Gillam EM, Guo Z, and Guengerich FP (1994) Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties. Arch Biochem Biophys 312: 59-66.[CrossRef][Medline]
Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261: 5051-5060.[Abstract/Free Full Text]
Guengerich FP and Turvy CG (1991) Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 256: 1189-1194.[Abstract/Free Full Text]
Gut J, Catin T, Dayer P, Kronbach T, Zanger U, and Meyer UA (1986) Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J Biol Chem 261: 11734-11743.[Abstract/Free Full Text]
Gut J, Gasser R, Dayer P, Kronbach T, Catin T, and Meyer UA (1984) Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation. FEBS Lett 173: 287-290.[CrossRef][Medline]
Hanna IH, Reed JR, Guengerich FP, and Hollenberg PF (2000) Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Arch Biochem Biophys 376: 206-216.[CrossRef][Medline]
Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11: 773-779.[CrossRef][Medline]
Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, and Funae Y (1996) Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 51: 1041-1050.[CrossRef][Medline]
Jenkins RE, Kitteringham NR, Hunter CL, Webb S, Hunt TJ, Elsby R, Watson RB, Williams D, Pennington SR, and Park BK (2006) Relative and absolute quantitative expression profiling of cytochromes P450 using isotope-coded affinity tags. Proteomics 6: 1934-1947.[CrossRef][Medline]
Kamdem LK, Meineke I, Koch I, Zanger UM, Brockmoller J, and Wojnowski L (2004) Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone. Naunyn Schmiedebergs Arch Pharmacol 370: 71-77.[Medline]
Kawano S, Kamataki T, Yasumori T, Yamazoe Y, and Kato R (1987) Purification of human liver cytochrome P-450 catalyzing testosterone 6 beta-hydroxylation. J Biochem 102: 493-501.[Abstract/Free Full Text]
King BP, Leathart JB, Mutch E, Williams FM, and Daly AK (2003) CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 55: 625-629.[CrossRef][Medline]
Komori M, Hashizume T, Ohi H, Miura T, Kitada M, Nagashima K, and Kamataki T (1988) Cytochrome P-450 in human liver microsomes: high-performance liquid chromatographic isolation of three forms and their characterization. J Biochem 104: 912-916.[Abstract/Free Full Text]
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383-391.[CrossRef][Medline]
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.[CrossRef][Medline]
Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Delivery Rev 54: 1271-1294.[CrossRef][Medline]
Lane CS, Nisar S, Griffiths WJ, Fuller BJ, Davidson BR, Hewes J, Welham KJ, Patterson LH (2004) Identification of cytochrome P450 enzymes in human colorectal metastases and the surrounding liver: a proteomic approach. Eur J Cancer 40: 2127-2134.[CrossRef][Medline]
Lasker JM, Raucy J, Kubota S, Bloswick BP, Black M, and Lieber CS (1987) Purification and characterization of human liver cytochrome P-450-ALC. Biochem Biophys Res Commun 148: 232-238.[CrossRef][Medline]
Lasker JM, Wester MR, Aramsombatdee E, and Raucy JL (1998) Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353: 16-28.[CrossRef][Medline]
Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62: 162-172.[Abstract/Free Full Text]
Matsubara T, Koike M, Touchi A, Tochino Y, Sugeno K (1976) Quantitative determination of cytochrome P-450 in rat liver homogenate. Anal Biochem 75: 596-603.[CrossRef][Medline]
Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370-2378.[Free Full Text]
Perrett HF, Barter ZE, Edwards RJ, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2006) The use of recombinantly expressed CYP3A5 as standards for immuno-quantification of hepatic CYP3A5 can result in underestimation of its abundance. Drug Metab Rev 38: 109.
Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2004) Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34: 151-178.[CrossRef][Medline]
Ng PS, Imaoka S, Hiroi T, Osada M, Niwa T, Kamataki T, and Funae Y (2003) Production of inhibitory polyclonal antibodies against cytochrome P450s. Drug Metab Pharmacokinet 18: 163-172.[CrossRef][Medline]
Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6: 140-148.[CrossRef][Medline]
Sandhu P, Baba T, and Guengerich FP (1993) Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Arch Biochem Biophys 306: 443:450.[CrossRef][Medline]
Shimada T, Misono KS, and Guengerich FP (1986) Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J Biol Chem 261: 909-921.[Abstract/Free Full Text]
Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423.[Abstract/Free Full Text]
Soucek P (1999) Expression of cytochrome P450 2A6 in Escherichia coli: purification, spectral and catalytic characterization, and preparation of polyclonal antibodies. Arch Biochem Biophys 370: 190-200.[CrossRef][Medline]
Tateishi T, Watanabe M, Moriya H, Yamaguchi S, Sato T, and Kobayashi S (1999) No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 57: 935-939.[CrossRef][Medline]
von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, and Kivisto KT (2004) Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 75: 172-183.[CrossRef][Medline]
Wandel C, Bocker RH, Bohrer H, deVries JX, Hofmann W, Walter K, Kleingeist B, Neff S, Ding R, Walter-Sack I, et al. (1998) Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally. Drug Metab Dispos 26: 110-114.[Abstract/Free Full Text]
Wang P, Mason PS, and Guengerich FP (1980) Purification of human liver cytochrome P-450 and comparison to the enzyme isolated from rat liver. Arch Biochem Biophys 199: 206-219.[CrossRef][Medline]
Wang PP, Beaune P, Kaminsky LS, Dannan GA, Kadlubar FF, Larrey D, and Guengerich FP (1983) Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry 22: 5375-5383.[CrossRef][Medline]
Wang YH, Jones DR, and Hall SD (2005) Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 33: 664-671.[Abstract/Free Full Text]
Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA, Guzelian PS (1985) Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci U S A 82: 6310-6314.[Abstract/Free Full Text]
Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31: 755-761.[Abstract/Free Full Text]
Wilson ZE, Ellis SW, Edwards RJ, Tucker GT, and Rostami-Hodjegan A (2005) Implications of the disparity in relative holo:apo-protein contents of different standards used for immunoquantification of hepatic cytochrome P450 3A4 (CYP3A4). Drug Metab Rev 37: 77.
Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, Schwab M, and Zanger UM (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38: 978-988.[CrossRef][Medline]
Wrighton SA, Thomas PE, Ryan DE, and Levin W (1987a) Purification and characterization of ethanol-inducible human hepatic cytochrome P-450HLj. Arch Biochem Biophys 258: 292-297.[CrossRef][Medline]
Wrighton SA, Thomas PE, Willis P, Maines SL, Watkins PB, Levin W, and Guzelian PS (1987b) Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats. J Clin Invest 80: 1017-1022.[Medline]
Yang TJ, Krausz KW, Shou M, Yang SK, Buters JT, Gonzalez FJ, and Gelboin HV (1998) Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol 55: 1633-1640.[CrossRef][Medline]
Yun CH, Shimada T, and Guengerich FP (1991) Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol 40: 679-685.[Abstract]
Yun CH, Miller GP, and Guengerich FP (2000) Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. Biochemistry 39: 11319-11329.[CrossRef][Medline]
This article has been cited by other articles:
|
|
|
|
 
A.-M. Yu, J. Qu, M. A. Felmlee, J. Cao, and X.-L. Jiang
Quantitation of Human Cytochrome P450 2D6 Protein with Immunoblot and Mass Spectrometry Analysis
Drug Metab. Dispos.,
January 1, 2009;
37(1):
170 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. Dennison, M. A. Mohutsky, R. J. Barbuch, S. A. Wrighton, and S. D. Hall
Apparent High CYP3A5 Expression Is Required for Significant Metabolism of Vincristine by Human Cryopreserved Hepatocytes
J. Pharmacol. Exp. Ther.,
October 1, 2008;
327(1):
248 - 257.
[Abstract]
[Full Text]
[PDF]
|
|
|
![[Feedback]](/icons/banner/feedbackACT.gif)
![[For Subscribers]](/icons/banner/subscriberACT.gif)
![[Archive]](/icons/banner/archiveACT.gif)
![[Search]](/icons/banner/searchACT.gif)
![[Contents]](/icons/banner/tocACT.gif)
Top
Abstract
Materials and Methods
